Incidence and Predictors of Adverse Drug Events Among People Receiving Drug Resistant Tuberculosis Treatment in Uganda: 8-Year Retrospective Cohort Study

Marble Nasasira,1 Joan N Kalyango,1,2 Ezekiel Mupere,3 Joseph Baruch Baluku4,5 1Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda; 2Department of Pharmacy, Makerere University College of Health Sciences, Kampala, Uganda; 3Department of Paediatrics and Child...

Full description

Bibliographic Details
Main Authors: Nasasira M, Kalyango JN, Mupere E, Baluku JB
Format: Article
Language:English
Published: Dove Medical Press 2022-12-01
Series:Therapeutics and Clinical Risk Management
Subjects:
Online Access:https://www.dovepress.com/incidence-and-predictors-of-adverse-drug-events-among-people-receiving-peer-reviewed-fulltext-article-TCRM
_version_ 1797980790364045312
author Nasasira M
Kalyango JN
Mupere E
Baluku JB
author_facet Nasasira M
Kalyango JN
Mupere E
Baluku JB
author_sort Nasasira M
collection DOAJ
description Marble Nasasira,1 Joan N Kalyango,1,2 Ezekiel Mupere,3 Joseph Baruch Baluku4,5 1Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda; 2Department of Pharmacy, Makerere University College of Health Sciences, Kampala, Uganda; 3Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda; 4Division of Pulmonology, Kiruddu National Referral Hospital, Kampala, Uganda; 5Makerere University Lung Institute, Kampala, UgandaCorrespondence: Marble Nasasira, Tel +256 778443346, Email marblenasasira@gmail.comBackground: Adverse drug events (ADEs) are regarded as the most essential therapeutic issue during management of drug-resistant tuberculosis (DR-TB) due to the long duration of therapy and concurrent use of many second-line medications. This study aimed to determine the incidence and factors associated with ADEs among patients receiving DR-TB treatment at Mulago hospital in Uganda.Methods: A retrospective cohort study was conducted among 417 DR-TB patient records at Mulago National Referral Hospital from January 2013 to December 2020. Using the data abstraction form, data were collected on socio-demographic and clinical factors, adverse drug events and treatment follow-up time. Data were double entered in Epi data version 3.2 and later exported to Stata version 14.0 for analysis. The incidence rate of adverse drug events was computed using number of cases of ADE divided by overall patient follow-up time. Poisson regression model was used to determine the factors associated with ADEs. The predictors were considered significant at if p< 0.05.Results: The overall incidence was 5.56 ADEs per 100 person months (95% confidence interval (CI) 5.01, 6.15). Treatment regimens containing an aminoglycoside (incident rate ratio (IRR) 1.106, 95% CI 1.005– 1.216 p=0.0391), linezolid (IRR 1.145, 95% CI 1.008– 1.229 p = 0.037) or pyrazinamide (IRR 1.226, 95% CI 1.072– 1.401 p = 0.003) and the treatment duration (in months) (IRR 1.005, 95% CI 1.001– 1.010 p = 0.042) were associated with ADEs.Conclusion: Regimens containing aminoglycosides, linezolid, or pyrazinamide and increase in treatment duration (months) were associated with an increased risk of ADEs. Clinicians should quickly adopt all oral shorter treatment regimens to obviate the need for aminoglycosides and reduce exposure duration.Keywords: adverse drug events, drug-resistant tuberculosis, Uganda
first_indexed 2024-04-11T05:59:21Z
format Article
id doaj.art-16a1ebfb34d845b9a3893c5a0c8bac8e
institution Directory Open Access Journal
issn 1178-203X
language English
last_indexed 2024-04-11T05:59:21Z
publishDate 2022-12-01
publisher Dove Medical Press
record_format Article
series Therapeutics and Clinical Risk Management
spelling doaj.art-16a1ebfb34d845b9a3893c5a0c8bac8e2022-12-22T04:41:47ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2022-12-01Volume 181117112780378Incidence and Predictors of Adverse Drug Events Among People Receiving Drug Resistant Tuberculosis Treatment in Uganda: 8-Year Retrospective Cohort StudyNasasira MKalyango JNMupere EBaluku JBMarble Nasasira,1 Joan N Kalyango,1,2 Ezekiel Mupere,3 Joseph Baruch Baluku4,5 1Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda; 2Department of Pharmacy, Makerere University College of Health Sciences, Kampala, Uganda; 3Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda; 4Division of Pulmonology, Kiruddu National Referral Hospital, Kampala, Uganda; 5Makerere University Lung Institute, Kampala, UgandaCorrespondence: Marble Nasasira, Tel +256 778443346, Email marblenasasira@gmail.comBackground: Adverse drug events (ADEs) are regarded as the most essential therapeutic issue during management of drug-resistant tuberculosis (DR-TB) due to the long duration of therapy and concurrent use of many second-line medications. This study aimed to determine the incidence and factors associated with ADEs among patients receiving DR-TB treatment at Mulago hospital in Uganda.Methods: A retrospective cohort study was conducted among 417 DR-TB patient records at Mulago National Referral Hospital from January 2013 to December 2020. Using the data abstraction form, data were collected on socio-demographic and clinical factors, adverse drug events and treatment follow-up time. Data were double entered in Epi data version 3.2 and later exported to Stata version 14.0 for analysis. The incidence rate of adverse drug events was computed using number of cases of ADE divided by overall patient follow-up time. Poisson regression model was used to determine the factors associated with ADEs. The predictors were considered significant at if p< 0.05.Results: The overall incidence was 5.56 ADEs per 100 person months (95% confidence interval (CI) 5.01, 6.15). Treatment regimens containing an aminoglycoside (incident rate ratio (IRR) 1.106, 95% CI 1.005– 1.216 p=0.0391), linezolid (IRR 1.145, 95% CI 1.008– 1.229 p = 0.037) or pyrazinamide (IRR 1.226, 95% CI 1.072– 1.401 p = 0.003) and the treatment duration (in months) (IRR 1.005, 95% CI 1.001– 1.010 p = 0.042) were associated with ADEs.Conclusion: Regimens containing aminoglycosides, linezolid, or pyrazinamide and increase in treatment duration (months) were associated with an increased risk of ADEs. Clinicians should quickly adopt all oral shorter treatment regimens to obviate the need for aminoglycosides and reduce exposure duration.Keywords: adverse drug events, drug-resistant tuberculosis, Ugandahttps://www.dovepress.com/incidence-and-predictors-of-adverse-drug-events-among-people-receiving-peer-reviewed-fulltext-article-TCRMadverse drug eventsdrug-resistant tuberculosisuganda
spellingShingle Nasasira M
Kalyango JN
Mupere E
Baluku JB
Incidence and Predictors of Adverse Drug Events Among People Receiving Drug Resistant Tuberculosis Treatment in Uganda: 8-Year Retrospective Cohort Study
Therapeutics and Clinical Risk Management
adverse drug events
drug-resistant tuberculosis
uganda
title Incidence and Predictors of Adverse Drug Events Among People Receiving Drug Resistant Tuberculosis Treatment in Uganda: 8-Year Retrospective Cohort Study
title_full Incidence and Predictors of Adverse Drug Events Among People Receiving Drug Resistant Tuberculosis Treatment in Uganda: 8-Year Retrospective Cohort Study
title_fullStr Incidence and Predictors of Adverse Drug Events Among People Receiving Drug Resistant Tuberculosis Treatment in Uganda: 8-Year Retrospective Cohort Study
title_full_unstemmed Incidence and Predictors of Adverse Drug Events Among People Receiving Drug Resistant Tuberculosis Treatment in Uganda: 8-Year Retrospective Cohort Study
title_short Incidence and Predictors of Adverse Drug Events Among People Receiving Drug Resistant Tuberculosis Treatment in Uganda: 8-Year Retrospective Cohort Study
title_sort incidence and predictors of adverse drug events among people receiving drug resistant tuberculosis treatment in uganda 8 year retrospective cohort study
topic adverse drug events
drug-resistant tuberculosis
uganda
url https://www.dovepress.com/incidence-and-predictors-of-adverse-drug-events-among-people-receiving-peer-reviewed-fulltext-article-TCRM
work_keys_str_mv AT nasasiram incidenceandpredictorsofadversedrugeventsamongpeoplereceivingdrugresistanttuberculosistreatmentinuganda8yearretrospectivecohortstudy
AT kalyangojn incidenceandpredictorsofadversedrugeventsamongpeoplereceivingdrugresistanttuberculosistreatmentinuganda8yearretrospectivecohortstudy
AT muperee incidenceandpredictorsofadversedrugeventsamongpeoplereceivingdrugresistanttuberculosistreatmentinuganda8yearretrospectivecohortstudy
AT balukujb incidenceandpredictorsofadversedrugeventsamongpeoplereceivingdrugresistanttuberculosistreatmentinuganda8yearretrospectivecohortstudy